Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Corbus Pharmaceuticals Holdings, Inc. CRBP

Healthcare  —  Biotechnology
7.14 (0.31) (4.16%) as of 25 Sep
Market cap
$144.1M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Business Profile

Updated before January 2025

Company Overview

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage pharmaceutical company dedicated to the development and commercialization of innovative therapies for rare, chronic, and serious inflammatory and fibrotic diseases. Founded in 2009 and headquartered in Norwood, Massachusetts, CRBP has established itself as a leader in the biotechnology sector, focusing on addressing unmet medical needs. The company is led by a team of seasoned professionals, including its CEO, Yuval Cohen, Ph.D., who has been instrumental in steering the company’s strategic direction. Other key members of the leadership team include Sean Moran, the Chief Financial Officer, and Rachael Brake, Ph.D., the Chief Scientific Officer.

Core Business Segments

CRBP’s core business revolves around the development of novel therapeutics targeting the endocannabinoid system and other pathways involved in inflammation and fibrosis. The company’s primary focus is on the following product categories:

Lenabasum

Lenabasum is CRBP’s flagship product, a synthetic oral endocannabinoid-mimetic drug designed to resolve inflammation and halt fibrosis. It is being developed for the treatment of rare diseases such as systemic sclerosis, dermatomyositis, and cystic fibrosis. Lenabasum has shown promising results in clinical trials, positioning it as a potential game-changer in the treatment of these conditions.

CRB-601 and CRB-602

CRBP is also advancing its pipeline with CRB-601 and CRB-602, monoclonal antibodies targeting integrins involved in inflammatory and fibrotic pathways. These candidates are in preclinical development and represent the company’s commitment to expanding its therapeutic portfolio.

Research and Development Services

In addition to its proprietary products, CRBP offers research and development services, leveraging its expertise in drug discovery and development to collaborate with academic institutions and other pharmaceutical companies.

Business Model

CRBP operates on a business model that integrates cutting-edge research, strategic partnerships, and a focus on rare diseases. The company generates revenue primarily through licensing agreements, milestone payments, and potential future product sales. By targeting niche markets with high unmet medical needs, CRBP aims to maximize its impact and profitability. The company also collaborates with patient advocacy groups and regulatory agencies to ensure its therapies address the specific needs of patients.

Strategic Direction

CRBP’s strategic direction is centered on advancing its clinical pipeline, expanding its therapeutic focus, and achieving long-term sustainability. Key elements of its strategy include:

  • Pipeline Expansion: CRBP is actively exploring new indications for its existing products and developing additional candidates to address a broader range of diseases.
  • Global Reach: The company aims to expand its presence in international markets through strategic partnerships and collaborations.
  • Sustainability Goals: CRBP is committed to minimizing its environmental footprint by adopting sustainable practices in its operations and supply chain.
  • Innovation: The company continues to invest in research and development to stay at the forefront of scientific advancements in inflammation and fibrosis.

Competitive Landscape

CRBP operates in a highly competitive environment, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Bristol-Myers Squibb: A global leader in immunology and fibrosis therapies.
  • FibroGen, Inc.: Specializes in the development of treatments for fibrotic diseases.
  • Galapagos NV: Focuses on inflammation and fibrosis with a robust pipeline of drug candidates.
  • Vertex Pharmaceuticals: A leader in cystic fibrosis therapies.

Despite the competition, CRBP differentiates itself through its focus on rare diseases and its innovative approach to targeting the endocannabinoid system.

Risk Factors

CRBP faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The approval process for new drugs is lengthy and uncertain, posing a significant risk to the company’s pipeline.
  • Market Dependence: CRBP’s reliance on a limited number of products increases its vulnerability to market fluctuations and competition.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply chain, particularly for raw materials and manufacturing.
  • Financial Constraints: As a clinical-stage company, CRBP relies heavily on external funding, which may not always be readily available.

Recent Developments

CRBP has made significant strides in recent years, including:

  • Clinical Trials: The company has advanced its clinical trials for Lenabasum, with promising results in systemic sclerosis and dermatomyositis.
  • Partnerships: CRBP has entered into strategic collaborations with leading academic institutions and pharmaceutical companies to accelerate its research and development efforts.
  • Corporate Strategies: The company has streamlined its operations to focus on its core strengths, reducing costs and improving efficiency.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of addressing rare diseases, providing an opportunity for CRBP to showcase its expertise.

Investment Considerations

Investors considering CRBP should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: CRBP’s focus on rare diseases and its novel approach to targeting the endocannabinoid system set it apart from competitors.
  • Experienced Leadership: The company’s management team has a proven track record in the pharmaceutical industry.
  • Strategic Partnerships: Collaborations with leading institutions enhance CRBP’s research capabilities and market reach.

Risks

  • Clinical and Regulatory Uncertainty: The success of CRBP’s pipeline depends on the outcome of clinical trials and regulatory approvals.
  • Financial Dependence: The company’s reliance on external funding could pose challenges in the event of market downturns.
  • Competitive Pressure: CRBP operates in a crowded market, facing competition from larger, more established players.

Conclusion

Corbus Pharmaceuticals Holdings, Inc. is a promising player in the biotechnology sector, with a strong focus on rare diseases and innovative therapies. While the company faces significant challenges, its robust pipeline, experienced leadership, and strategic partnerships position it well for future growth. As CRBP continues to advance its clinical trials and expand its global presence, it remains an attractive option for investors seeking exposure to the biotech industry.